• Dopamenergic drugs and Anticholinergic drugs
• It’s a mnetaffinoid potentiator of dopamine, thus increasing the release and synthesis of dopamine.
• Inhibition of MAO-B, thus decreasing the metabolism of dopamine. This then increases the doncentration of dopamine in the brain.
• Ergot: Bromocriptine

Non-ergot: Pramipexole and Ropinirole

• Pramipexole – Dopamine3

Ropinirole – Dopamine2

Bromocriptine – General Dopamine agonist

• MAO-B inhibitors, they protect the neurons in the brain from further atrophy and thus decreasing the disease progression.
• They increase the dopamine concentration in the brain as well as help decrease the disease progression.
• They stop the stop the metabolism of L-Dopa to 3-O-Methyldopa, thus increasing the L-Dopa available to be converted to Dopamine.
• Istradephyline decreases the amount of “off”-periods during treatment, thus increasing the effectiveness of long-term treatment.
• Safinamide is a MOA dualist, thus it causes an increase in dopamine activity  and a decrease in glutamate realease.